Shares of Hikma Pharmaceuticals Plc (LON:HIK) have been assigned an average recommendation of “Hold” from the ten analysts that are covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is GBX 1,088.89 ($15.04).
HIK has been the topic of several analyst reports. Numis Securities reaffirmed a “buy” rating and set a GBX 1,300 ($17.96) price target on shares of Hikma Pharmaceuticals in a research report on Wednesday, December 20th. Morgan Stanley reiterated an “equal weight” rating and issued a GBX 1,100 ($15.20) price objective on shares of Hikma Pharmaceuticals in a report on Friday, December 1st. Jefferies Group upped their price objective on shares of Hikma Pharmaceuticals from GBX 1,045 ($14.44) to GBX 1,074 ($14.84) and gave the company a “hold” rating in a report on Monday, December 4th. Peel Hunt reiterated a “hold” rating and issued a GBX 1,390 ($19.20) price objective on shares of Hikma Pharmaceuticals in a report on Wednesday, November 15th. Finally, JPMorgan Chase & Co. decreased their price objective on shares of Hikma Pharmaceuticals from GBX 1,250 ($17.27) to GBX 1,000 ($13.82) and set a “neutral” rating on the stock in a report on Friday, November 10th.
Shares of Hikma Pharmaceuticals (HIK) opened at GBX 898.40 ($12.41) on Friday. Hikma Pharmaceuticals has a 1 year low of GBX 814.20 ($11.25) and a 1 year high of GBX 2,346 ($32.41). The stock has a market cap of $2,180.00 and a price-to-earnings ratio of 1,796.80.
About Hikma Pharmaceuticals
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.